- Home
- TENX vs LITS Comparison
TENX vs LITS Comparison
Compare TENX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENX | LITS |
|---|---|---|
| Founded | 1967 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 55.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TENX | LITS |
|---|---|---|
| Price | $12.17 | $1.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | 211.3K | ★ 679.7K |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $1.30 |
| 52 Week High | $14.22 | $9.00 |
Technical Indicators
Market Signals| Indicator | TENX | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | N/A |
| Support Level | $11.70 | N/A |
| Resistance Level | $13.00 | N/A |
| Average True Range (ATR) | 0.98 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 55.63 | 0.00 |
Price Performance
Historical ComparisonAbout TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.